Yüksel Ürün: As a GU oncologist my non-GU key highlights from ASCO24

Yüksel Ürün shared on X/Twitter:

“As a GU oncologist my non-GU key highlights from ASCO24.

1. LAURA:LBA4: Unresectable Stage III EGFR-Mutated NSCLC:
Suresh S. Ramalingam, Winship Cancer Institute of Emory University

• Adjuvant osimertinib vs. placebo after definitive chemoradiation.
• mPFS: 39 months (OSI) vs. 5.6 months (placebo).
• 2-year PFS: 65% (OSI) vs. 13% (placebo).

2. CROWN: LBA8503 Advanced ALK+ NSCLC: Ben Solomon, Peter Mac Cancer Center.

• Lorlatinib vs. crizotinib
• 5-year PFS: 60% (lorlatinib) vs. 8% (crizotinib).

3. ADRIATIC: LBA5 Limited SCLC: David R. Spigel, Sarah Cannon Cancer Institute.

• Adjuvant durvalumab vs. placebo post-chemo radiotherapy
• mPFS: 16 months (D) vs. 9 months (placebo)
• mOS: 55 months (D) vs. 33 months (placebo)

4. ESOPEC: LBA1: Locally Advanced GEJ Adenocarcinoma: J.Hoepner, Bielefeld University.

• Periop chemotherapy (FLOT) vs. preop CRT (CROSS)
• mOS: 66 months (FLOT) vs. 37 months (CROSS)
• 3-year OS: 57% (FLOT) vs. 50% (CROSS)

5. NADINA: LBA2: Stage III Melanoma: Christian U. Blank of The Netherlands Cancer Institute.

• Neoadjuvant NIVO + IPI vs. adjuvant NIVO
• 12-month EFS: 83% (neoadj) vs. 57% (adjuvant)

6. Destiny Breast 06: LBA100 HR+ Metastatic Breast Cancer: Giuseppe Curigliano.

• T-DXd vs. chemotherapy
• mPFS: 13 months (T-DXd) vs. 8 months (chemo)
• ORR: 57% (T-DXd) vs. 32% (chemo).”

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.